RS

Rashmi Singh

Active Director Director DIN 09802361
DIN 09802361 First appointment Nov 2022 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2022
Shareholding value •••• Premium profile

About Rashmi Singh

Data last updated:

Rashmi Singh is a Director at Sdrv Homoeo Pharma Private Limited (since 2022). The company operates in Chemicals. Sdrv Homoeo Pharma Private Limited reported revenue of ₹25,879 (FY 2023).

DIN 09802361
Primary Designation Director
Industry Chemicals
First Appointment 24 Nov 2022
Oldest Company Age 3 yrs
Largest company Sdrv Homoeo Pharma Private Limited · ₹25,879 (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sdrv Homoeo Pharma Private Limited U24239UP2022PTC173936
Director24 Nov 20222022₹25,879 (FY 2023)Active

Board colleagues of Rashmi Singh

Directorship timeline

Open interactive timeline →
Sdrv Homoeo Pharma Private Limited
Premium access

Shareholding and investment profile for Rashmi Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rashmi Singh

Rashmi Singh currently holds 1 directorship: Sdrv Homoeo Pharma Private Limited (Director, since 24 Nov 2022, revenue ₹25,879 (FY 2023)).

Rashmi Singh was first appointed on 24 Nov 2022 as Director at Sdrv Homoeo Pharma Private Limited.

The current boards of Rashmi Singh's companies include Dhirendra Pratap Singh (Sdrv Homoeo Pharma Private Limited), Ritu Singh (Sdrv Homoeo Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available